Bleomycin is indicated for palliation and treatment adjuvant to surgery and radiation therapy of the following neoplasms: Squamous cell carcinoma of the skin, head and neck and oesophagus (primary indication).
Squamous cell carcinoma of the larynx, penis and uterine cervix.
Squamous cell carcinoma of the bronchus (response infrequent).
Choriocarcinoma and embryonal cell carcinoma of the testis.
Advanced Hodgkin's disease and other lymphomas.
Note: Use of bleomycin after radiation therapy is less successful than use before radiation therapy.
Bleomycin is bone marrow sparing and may be used when other cytotoxic agents are contraindicated.